Q-omics provides the consensus-scored SNHG6 profile across patient tissues and cancer cell-line models. SNHG6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNHG6 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SNHG6 RNA expression shows 17,878 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where SNHG6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG6 survival associations across molecular data types. SNHG6 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG6 RNA expression–survival associations across cancer types. High SNHG6 expression shows unfavorable associations in UVM, ACC, LIHC, KICH, KIRP and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNHG6 RNA expression.
This table summarizes SNHG6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG6 shows higher tumor expression in KIRC, COAD, LIHC, HNSC, KIRP and READ. The KIRC box plot shows higher SNHG6 RNA expression in tumor versus normal tissue (log2 FC = +1.071, t-test p < 0.001).
This table shows molecular features associated with SNHG6 in patient tissues and cancer cell lines. In patient samples, SNHG6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
